This health news summary covers significant topics including UnitedHealth tech unit's post-hack customer situation, new ...

Three scientists were recognized by the Lasker Awards for their work on the GLP-1 hormone. Others were honored for work to ...

The device is a variant of Neuralink's brain implant technology, in this case designed to "enable even those who have lost both eyes" to see, according to owner Elon Musk. Separately, progress is ...

U.S. telehealth company Hims & Hers Health on Wednesday said it will sell compounded versions of Novo Nordisk's popular ...

One of the world’s largest drug manufacturers is suing a small east metro wellness center over the way it marketed and sold a ...

With its line-up of sweet snacks, Hershey isn’t known as a purveyor of diet foods. However, the company’s newest products are ...

Starting in the 1990s, Knudsen, the head of GLP-1 therapeutics at Novo Nordisk, and her team built on these breakthroughs to develop treatments for diabetes (Ozempic) and obesity (Wegovy), extending ...

U.S. Senator Bernie Sanders said on Tuesday he received confirmation from major generic pharmaceutical companies that they ...

Around 25 percent of U.S. adults said they would consider using prescription weight loss medications, like Ozempic or Wegovy, ...

Nearly 4.4 million adult New Yorkers, or 30%, have obesity, but access to weight-loss medications varies based on a variety ...

Chinese pharmaceutical and biotech companies are leading development of glucagon-like peptide-1 receptor agonists as Novo Nordisk A/S and Eli Lilly and Co. edge closer to launching blockbuster ...

Physicians and health professionals from around the country demanded that Novo Nordisk and Eli Lilly make their novel diabetes and obesity medications affordable and accessible to all.